Sanctuary Advisors LLC cut its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 57.9% ...

Takeda Pharmaceutical teamed up with the Boston Celtics to raise awareness of rare diseases at the C’s-Cavaliers game on ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

The positive results of the Phase 3 VERIFY study across the primary and all key secondary endpoints provide compelling evidence of the potential for rusfertide as a first-in-class ...

The company highlighted that about 90% of proteins associated with diseases cannot be targeted with traditional therapies due ...

This metric takes into account a company's operating cash flow and ... These are only a few of the key metrics included in Takeda Pharmaceutical Co.'s strong Value grade, but they help show ...

TOKYO -- Takeda Pharmaceutical aims to sell a vaccine for dengue in Japan as more business travelers go to Southeast Asian and Latin American destinations where the mosquito-borne viral disease is ...

Meanwhile, a New Drug Application (NDA) for another one of Ascentage Pharma’s key drug candidates, the novel Bcl-2 selective inhibitor lisaftoclax (APG-2575), has already been accepted and granted the ...